Search results
CAR-T cell therapy to treat blood cancers unlikely to increase risk of secondary cancers
UPI· 2 days agoA study of more than 700 patients treated at Stanford University found that the risk of secondary...
Could These Contaminants Play a Role in Parkinson's Disease?
Mercola· 4 days agoOver the last 30 years, the Environmental Protection Agency has failed to complete the cleanup and remediation of the contaminated of soil and water at Camp Lejeune.6 How did we reach this point ...
Touched by cancer: Todd Riley will host a fundraiser and ride in this year's Pelotonia.
Times Recorder via Yahoo News· 2 days ago“That’s what motivates me to keep doing this.” Riley saw a 2018 article for Pelotonia about its 10th...
With A Similar Revenue Base, Is Johnson & Johnson A Better Pick Despite The 30% Fall In Tesla Stock...
Forbes· 3 days agoIn this case, although these companies are from different sectors, they share a similar revenue base...
Cardiovascular conditions now the second-highest reimbursement category, Sun Life says
HR Dive· 1 day agoCardiovascular conditions — including congenital heart defects, heart failure, stroke and hypertension — moved into the second spot for stop-loss reimbursements in 2023 for the first time, an ...
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
MedPage Today· 3 days agoOnly one of 724 patients treated with chimeric antigen receptor (CAR) T-cell therapy for B-cell...
Roy Scheider Went From Amateur Boxer To Established Actor — Read About the ‘Jaws’ Star Here
Bradenton Herald· 4 days ago“You’re gonna need a bigger boat,” he famously said
BeiGene, Ltd. (NASDAQ:BGNE) Receives $251.93 Average PT from Brokerages
ETF DAILY NEWS· 4 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has received an average rating of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat reports. Two research analysts have ...
Man creates his own working bionic hand after medical insurance company refused to pay for one
UNILAD· 2 days agoWhile prosthetics are certainly a lot more common than they were 20 years ago, they are still pretty...
Oppenheimer Lowers Cellectis (NASDAQ:CLLS) Price Target to $10.00
ETF DAILY NEWS· 23 hours agoCellectis (NASDAQ:CLLS – Get Free Report) had its target price dropped by Oppenheimer from $11.00 to $10.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently ...